Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 5/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8338373 | 1.00 | ABCC9 (0.73) | ABCC9 | |
| SCHEMBL8338376 | 1.00 | ABCC9 (0.73) | ABCC9 | |
| SCHEMBL7141377 | 0.92 | ABCC9 (0.62) | ABCC9 | |
| SCHEMBL8343672 | 0.89 | ABCC9 (0.64) | ABCC9 | |
| SCHEMBL8343667 | 0.89 | ABCC9 (0.64) | ABCC9 | |
| SCHEMBL8338365 | 0.89 | ABCC9 (0.64) | ABCC9 | |
| SCHEMBL8343026 | 0.89 | ABCC9 (0.64) | ABCC9 | |
| SCHEMBL7722209 | 0.89 | ABCC9 (0.64) | ABCC9 | |
| SCHEMBL3303489 | 0.89 | ABCC9 (0.64) | ABCC9 | |
| SCHEMBL8343023 | 0.89 | ABCC9 (0.64) | ABCC9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5908860-A | Bicyclic compounds with pharmaceutical activity | SMITHKLINE BEECHAM PLC, (GB) | 1999-06-01 | — | — | US | claimed |
| EP-0673373-A1 | BICYCLIC COMPOUNDS WITH PHARMACEUTICAL ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1995-09-27 | — | — | EP | claimed |
| WO-1994013656-A1 | BICYCLIC COMPOUNDS WITH PHARMACEUTICAL ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1994-06-23 | — | — | WO | claimed |
| US-20160318892-A1 | PRODRUG COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| US-20160318892-A1 | PRODRUG COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| US-20160318892-A1 | PRODRUG COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| US-5908860-A | Bicyclic compounds with pharmaceutical activity | SMITHKLINE BEECHAM PLC, (GB) | 1999-06-01 | — | — | US | disclosed |
| EP-0673373-A1 | BICYCLIC COMPOUNDS WITH PHARMACEUTICAL ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1995-09-27 | — | — | EP | disclosed |
| WO-1994013656-A1 | BICYCLIC COMPOUNDS WITH PHARMACEUTICAL ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318892-A1 | PRODRUG COMPOUNDS | SCN1B, CACNA1E, SCN2B | ABCC9 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.